Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-1.73/-1.34
|
|
Enterprise Value
42.01M
|
| Balance Sheet |
|
Book Value Per Share
2.07
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
14.97M
|
|
Operating Revenue Per Share
0.33
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/11/16 02:45 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines. |

0.795 
